Related Experiment Video
Updated: May 26, 2025

Chronic Constriction of the Sciatic Nerve and Pain Hypersensitivity Testing in Rats
Published on: March 13, 2012
Spinal KCC2 Mediates the Modulation Effect of HDAC2 on Bone Cancer Pain in Rats
Tongxuan Wang1, Yalin Li2,3, Xinran Hou2,4
1Department of Anesthesiology, Chongqing Cancer Institute, Chongqing University Cancer Hospital, Chongqing Cancer Hospital, 181# Hanyu Road, Shapingba District, 400030 Chongqing, China.
Background:
Bone cancer pain is a global medical concern with limited treatment options that significantly reduce the quality of life for cancer patients. Therefore, identifying a promising therapeutic target for bone cancer pain is urgently needed.
Objective:
Our previous research indicated that KCC2 may be associated with the modulation of HDAC2 in a rat model of bone cancer pain. The current study aimed to investigate whether KCC2 in the lumbar spinal cord is a key downstream molecule in the modulation of HDAC2 related to bone cancer pain.
Methods:
In this study, we assessed the expression levels of KCC2 and HDAC2 in the lumbar spinal cord of rats with bone cancer pain using Western blotting and RT-PCR. Mechanical hyperalgesia was evaluated using Von Frey hairs, and immunofluorescence was employed to localize KCC2 in central nervous system cells.
Results:
The expression of KCC2 was down-regulated in a time-dependent manner in the lumbar spinal cord of rats with bone cancer pain. Furthermore, the use of an RNAinterfering lentivirus targeting HDAC2 restored KCC2 expression and alleviated mechanical hyperalgesia in these rats. Notably, the analgesic effect of the HDAC2-targeting lentivirus was completely reversed by the KCC2 inhibitor VU0240551.
Conclusion:
KCC2 in the lumbar spinal cord mediated the modulation of HDAC2 in rat models of bone cancer pain, suggesting that KCC2 could be a promising therapeutic target for treating bone cancer pain.
Insights
KCC2 in the spinal cord is a key target for bone cancer pain. Targeting HDAC2 restores KCC2 expression, alleviating pain, but blocking KCC2 reverses this effect.
Area of Science:
- Neuroscience
- Pain Research
- Molecular Biology
Background:
- Bone cancer pain significantly impacts patient quality of life.
- Limited therapeutic options highlight the need for novel treatment targets.
- Previous work suggested a link between KCC2 and HDAC2 in bone cancer pain models.
Purpose of the Study:
- To investigate if KCC2 in the lumbar spinal cord is a critical downstream molecule modulated by HDAC2 in bone cancer pain.
- To explore the therapeutic potential of targeting KCC2 for bone cancer pain.
Main Methods:
- Assessed KCC2 and HDAC2 expression in rat lumbar spinal cord using Western blotting and RT-PCR.
- Evaluated mechanical hyperalgesia with Von Frey hairs.
- Localized KCC2 in central nervous system cells via immunofluorescence.
Main Results:
- KCC2 expression decreased over time in rats with bone cancer pain.
- Targeting HDAC2 with lentivirus restored KCC2 and reduced pain.
- A KCC2 inhibitor blocked the pain-relieving effects of the HDAC2-targeting lentivirus.
Conclusions:
- KCC2 in the lumbar spinal cord plays a crucial role in HDAC2 modulation in bone cancer pain.
- KCC2 represents a promising therapeutic target for managing bone cancer pain.
Related Concept Videos
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Inhibition of Cdk Activity
Histone Variants at the Centromere

